Jul. 10 at 10:15 PM
$RFL More B.S. posted today regarding SEC disclosure rules regarding material events, unfortunately, requires my response.
To be clear, yes, there is a 4-day trading window requirement regarding material events, at least, when last I checked a decade ago.
Now, unless those rules have been tightened, the poster unintentionally or intentionally omitted one very important fact.
The 4-day trading window requirement exists UNLESS THE COMPANY DOES NOT INFORM ANY STAKEHOLDER OF THAT EVENT AT THAT TIME OR SUBSEQUENT TO DISCLOSURE.
As an example, Orphazyme chose not to disclose the Phase-3 data of two Phase-3 trials in larger populations (ALS was one) because the primary endpoint miss was so bad it would have discouraged investors and biased FDA researchers during their MIPLYFFA Phase 2/3 deliberations. This is a FACT that company operatives on this board will omit when critiquing my posts regarding waiting until CHMP decides MIPLYFFA’s fate in Europe.
